Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biden’s Cancer Initiative May Intensify Industry, Government Collaboration

Executive Summary

Drug companies and NIH embrace Vice President’s call for moonshot to cure cancer; Amgen and Celgene join separate coalition to test 60 molecules in combination Phase II studies.

You may also be interested in...



Clinical Trial Challenges: FDA Wants More Prospective Studies, Validated Biomarkers

NIH Director Collins and FDA Commissioner Califf discuss difficulties with ‘big science,’ ‘small crappy trials,’ and ‘data landlords.’

Trump’s Election Could Bring ‘Best Of Times’ For Pharma

Obama administration wasn’t bad but had ‘less than thrilling moments,’ BIO exec says; former FDA Commissioner says leadership, not scientific, skill is key attribute for next agency chief.

Cancer 'Moonshot' Recommendations On R&D Have Strong Patient Focus

Blue ribbon panel has plenty of industry-friendly recommendations on ways to accelerate oncology science, but with the clock ticking down on the Obama Administration, the question is whether the recommendations have any political traction.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel